Biotechnology

WuXi Vaccines Receives Brazil's ANVISA GMP Certification

SUZHOU, China, Feb. 11, 2026 /PRNewswire/ -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that it has received Good Manufacturing Practices (GMP) certification for its fill and finish f...

2026-02-12 11:48 6165

Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications

HONG KONG, Feb. 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139,  a first-in-class IL-4Rα/ST2-targeting bispecific antibody, across seven indications. These i...

2026-02-11 17:01 7438

Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development

-   Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studies. -   In NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once...

2026-02-11 07:15 8870

On Site: "2026 China Forum on Source Innovation in New Drug Discovery" Concludes Successfully

SHANGHAI, Feb. 10, 2026 /PRNewswire/ -- As China's new drug R&D enters the "deep waters" of homogeneous competition, the path for followers has become increasingly crowded. Target congestion, rising costs, and intensifying global races have pushed the traditional follow-on model to its limits. Th...

2026-02-10 21:07 7045

AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases

CAMBRIDGE, Mass., Feb. 10, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceuti...

2026-02-10 21:00 7825

ArrayPatch Announces First Close of €3M Seed Round to Advance ITZ-DerMap™ for Treatment of Nail Fungus

CORK, Ireland, Feb. 10, 2026 /PRNewswire/ -- ArrayPatch Ltd, a biotech company developing innovative microneedle-based therapeutics, today announced the first close of its €3 million seed funding round, to advance its lead program ITZ-DerMap™, a novel therapeutic designed for the treatment of ...

2026-02-10 16:01 5021

From Morphology to Clinical Insights: Ozelle's AI-Powered Diagnostics at WHX Labs Dubai 2026

DUBAI, UAE, Feb. 10, 2026 /PRNewswire/ -- As WHX Labs Dubai 2026 opens today, visitors to Booth S1.D58 are invited to see how Ozelle transforms diagnostic testing into interactive, decision-ready workflows. Under the theme "AI × CBM: The Next-Generation of Complete Blood Morphology," the integrat...

2026-02-10 14:30 4542

Medical biotech Ferronova completes enrolment for gastric and oesophageal cancer image-guided surgery trial.

ADELAIDE, Australia, Feb. 10, 2026 /PRNewswire/ -- Australian company Ferronova announced today it has completed enrolment of patients for its two-year trial to progress commercialisation of FerroTrace, a novel nanoparticle image-guided surgery solution for hard-to-treat cancers. The technology ...

2026-02-10 09:30 5532

WAT Medical's EmeTerm Wearable Device Demonstrates Superior Control of Moderate to Severe Postoperative Nausea and Vomiting in JAMA Surgery-Published Clinical Trial

VANCOUVER, BC, Feb. 9, 2026 /PRNewswire/ -- WAT Medical is proud to announce the publication of a landmark randomized clinical trial inJAMA Surgery, one of the world's most reputable and high-impact surgical journals. The study confirms that the EmeTerm wristband — a wearable device utilizing tr...

2026-02-10 03:08 7520

Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

* Announces appointment of Claire M. Fraser, Ph.D., to its Board of Directors * Forms a global life sciences and diagnostics leader focused on high-volume testing in regulated applications * Announces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advance...

2026-02-09 21:44 9795

DIFF Biotech's Innovative Nasal Spray Influenza Vaccine Receives Clinical Trial Approval, Introducing a New Attenuation Pathway

HANGZHOU, China, Feb. 9, 2026 /PRNewswire/ -- Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) announced that its proprietary nasal spray influenza attenuated live vaccine, DIFF-flu, has recently received clinical trial approval as a Class 1.2 innovative vaccine fromChina's Nati...

2026-02-09 21:00 3985

Angel Yeast Indonesia Project: Strengthening Foundations through Technical Training and Building Consensus through Cultural Exchange

YICHANG, China, Feb. 6, 2026 /PRNewswire/ -- Angel Yeast Group (SH600298) recently welcomed 29 employees from Indonesia to its headquarters in Yichang, China, for a six-month structured training program. The initiative is designed to develop a cohort of skilled profes...

2026-02-07 09:31 20422

Neurophet Secures FDA 510(k) Clearance for "Neurophet AQUA AD Plus," Marking Its Third U.S. Regulatory Milestone

* Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet's leadership in AI-based Alzheimer's disease imaging analysis * Advanced analysis of neuroimaging features associated with cerebral microbleeds and edema supports imaging-based clinical decision-making and accelera...

2026-02-06 22:00 12472

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

* Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards * Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals * Validated system provides reliable, consistent carbon footprint data for clients I...

2026-02-06 21:00 11581

Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology

CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico")  (3696.HK),  a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment ofHalle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology. Dr. Z...

2026-02-06 21:00 8697

LakeShore Biopharma Announces Receipt of Buyer Group Notice and Postponement of Extraordinary General Meeting of Shareholders

BEIJING, Feb. 6, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics fo...

2026-02-06 20:00 10933

Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia

SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines,recently announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received Investigational New Drug (IND) clearance fromChina's Natio...

2026-02-06 20:00 7357

Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") prepares for the launch of PYQUVI™ (deflazacort) oral suspension, the first of a new branded-generic rare disease product line

BASKING RIDGE, N.J., Feb. 6, 2026 /PRNewswire/ -- Aucta Pharmaceuticals is pleased to announce the late January launch of PYQUVI oral suspension 22.75 mg/mL.  PYQUVI, a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older, is bioequi...

2026-02-06 19:59 4764

Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer

CHENGDU, China, Feb. 6, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application for its TROP2-directed ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) has been approv...

2026-02-06 17:00 8060

PharmaResearch Receives U.S. FDA Clearance to Initiate Phase 1 Clinical Trial of Nano Anticancer Drug, PRD-101

SEONGNAM, South Korea, Feb. 6, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEO:Jihoon Sohn) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PRD-101, enabling the initiation of a Phase 1 clinical trial inthe United ...

2026-02-06 15:20 7879
1 ... 18192021222324 ... 348